Sweden's Xintela Q2 loss narrows as income rises, costs drop
Sweden's Xintela Q2 loss narrows as income rises, costs drop
Overview
Sweden biopharma firm's Q2 income rose, loss before tax narrowed on higher sales, lower costs
Loss per share for Q2 improved to SEK 0.01 from SEK 0.02
Company secured SEK 30 mln convertible loan to accelerate XSTEM® development and repay debt
Outlook
Company did not provide specific guidance for future quarters or full-year results
Result Drivers
EQGEN PROJECT - Co said increased net sales in Q2 were driven by work on the EQGen project
LOWER COSTS - Co said reduced costs contributed to improved pre-tax result in Q2
Company press release: ID:nMFN8tYb4L
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| SEK 0.01 |
|
Reuters Recommended Reads
Aug 26 - Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Aug 26 - Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Aug 27 - Sweden's BioInvent Q2 net sales drop, loss widens
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)